The effect of acquired cisplatin resistance on sensitivity to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer cells

Oncology Research

Volumn 19, Issue 10-11, 2012, Pages 471-478

  Rho, Jin Kyung ^a   Choi, Yun Jung ^a,b   Choi, You Ri ^a   Kim, Sun Ye ^a   Choi, Su Jin ^c   Choi, Chang Min ^a   Na, Im Il ^c   Lees, Jae Cheol ^a,b  

^a University of Ulsan   (South Korea)

^b University of Science and Technology (UST)   (South Korea)

^c Korea Cancer Center Hospital   (South Korea)

Author keywords

Chemoresistance; Cisplatin; Epidermal growth factor receptor (EGFR) inhibitor; Lung cancer

Indexed keywords

AFATINIB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUORODEOXYGLUCOSE F 18; GEFITINIB; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CANCER SIZE; CELL ASSAY; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WILD TYPE;

EID: 84859734391     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504012X13285365944337     Document Type: Article

References (18)

1. Mok, T. S.; Wu, Y. L.; Thongprasert, S.; Yang, C. H.; Chu, D. T.; Saijo, N.; Sunpaweravong, P.; Han, B.; Margono, B.; Ichinose, Y.; Nishiwaki, Y.; Ohe, Y.; Yang, J. J.; Chewaskulyong, B.; Jiang, H.; Duffield, E. L.; Watkins, C. L.; Armour, A. A.; Fukuoka, M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361:947-957; 2009.
2. Maemondo, M.; Inoue, A.; Kobayashi, K.; Sugawara, S.; Oizumi, S.; Isobe, H.; Gemma, A.; Harada, M.; Yoshizawa, H.: Kinoshita, I.; Fujita, Y.; Okinaga, S.; Hirano, H.; Yoshimori, K.; Harada, T.; Oqura, T.; Ando, M.; Miyazawa, H.; Tanaka, T.; Saijo, Y.; Haqiwara, K.; Morita, S.; Nukiwa, T. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362:2380-2388; 2010.
3. Pao, W.; Miller, V. A. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions. J. Clin. Oncol. 23:2556-2568; 2005.
4. Chin, T. M.; Quinlan, M. P.; Singh, A.; Sequist, L. V.; Lynch, T. J.; Haber, D. A.; Sharma, S. V.; Settleman, J. Reduced erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: A cell culture model of second-line erlotinib treatment. Clin. Cancer Res. 14:6867-6876; 2008.
5. Yang, C. H.; Yu, C. J.; Shih, J. Y.; Chang, Y. C.; Hu, F. C.; Tsai, M. C.; Chen, K. Y.; Lin, Z. Z.; Huang, C. J.; Shun, C. T.; Huang, C. L.; Bean, J.; Cheng, A. L.; Pao, W.; Yang, P. C. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J. Clin. Oncol. 26:2745-2753; 2008.
6. Wu, J. Y.; Yu, C. J.; Shih, J. Y.; Yang, C. H.; Yang, P. C. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer. Lung Cancer 67:348-354; 2010.
7. Servidei, T.; Riccardi, A.; Mozzetti, S.; Ferlini, C.; Riccardi, R. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib. Int. J. Cancer 123:2939-2949; 2008.
8. Dai, Q.; Ling, Y. H.; Lia, M.; Zou, Y. Y.; Kroog, G.; Iwata, K. K.; Perez-Soler, R. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines. Clin. Cancer Res. 11:1572-1578; 2005.
9. Carmichael, J.; DeGraff, W. G.; Gazdar, A. F.; Minna, J. D.; Mitchell, J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemo-sensitivity testing. Cancer Res. 47:936-942; 1987.
10. Rho, J. K.; Choi, Y. J.; Lee, J. K.; Ryoo, B. Y.; Na, I. I.; Yang, S. H.; Lee, S. S.; Kim, C. H.; Yoo, Y. D.; Lee, J. C. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. Mol. Cancer Res. 7:1736-1743; 2009.
11. Cappuzzo, F.; Magrini, E.; Ceresoli, G. L.; Bartolini, S.; Rossi, E.; Ludovini, V.; Gregorc, V.; Ligorio, C.; Cancellieri, A.; Damiani, S.; Spreafico, A.; Paties, C. T.; Lombardo, L.; Calandri, C.; Bellezza, G.; Tonato, M.; Crinò, L. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 96:1133-1141; 2004.
12. Engelman, J. A.; Mukohara, T.; Zejnullahu, K.; Lifshits, E.; Borraaposs, A. M.; Gale, C. M.; Naumov, G. N.; Yeap, B. Y.; Jarrell, E.; Sun, J.; Tracy, S.; Zhao, X.; Heymach, J. V.; Johnson, B. E.; Cantley, L. C.; Jänne, P. A. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J. Clin. Invest. 116:2695-2706; 2006.
13. Yamasaki, F.; Johansen, M. J.; Zhang, D.; Krishnamurthy, S.; Felix, E.; Bartholomeusz, C.; Aquilar, R. J.; Kurisu, K.; Mills, G. B.; Hortobagyi, G. N.; Ueno, N. T. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res. 67:5779-5788; 2007.
14. She, Q. B.; Solit, D. B.; Ye, Q.; O'Reilly, K. E.; Lobo, J.; Rosen, N. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8:287-297; 2005.
15. McDermott, U.; Sharma, S. V.; Dowell, L.; Greninger, P.; Montagut, C.; Lamb, J.; Archibald, H.; Raudales, R.; Tam, A.; Lee, D.; Rothenberg, S. M.; Supko, J. G.; Sordella, R.; Ulkus, L. E.; Iafrate, A. J.; Maheswaran, S.; Njauw, C. N.; Tsao, H.; Drew, L.; Hanke, J. H.; Ma, X. J.; Erlander, M. G.; Gray, N. S.; Haber, D. A.; Settleman, J. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc. Natl. Acad. Sci. USA 104:19936-19941; 2007.
16. Sos, M. L.; Koker, M.; Weir, B. A.; Heynck, S.; Rabinovsky, R.; Zander, T.; Seeger, J. M.; Weiss, J.; Fischer, F.; Frommolt, P.; Michel, K.; Peifer, M.; Mermel, C.; Girard, L.; Peyton, M.; Gazdar, A. F.; Minna, J. D.; Garraway, L. A.; Kashkar, H.; Pao, W.; Meyerson, M.; Thomas, R. K. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 69:3256-3261; 2009.
17. Gong, Y.; Somwar, R.; Politi, K.; Balak, M.; Chmielecki, J.; Jiang, X.; Pao, W. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med. 4: e294; 2007.
18. Ling, Y. H.; Li, T.; Yuan, Z.; Haigentz, Jr., M.; Weber, T. K.; Perez-Soler, R. Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in asso ciation with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Mol. Pharmacol. 72:248-258; 2007.